95 related articles for article (PubMed ID: 17884270)
1. Telmisartan, an angiotensin II type-1 receptor blocker, improved insulin resistance in a schizophrenic patient treated with olanzapine: a case report.
Yamashita H; Yoda H; Maruki T; Toyoshima R
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):308-10. PubMed ID: 17884270
[No Abstract] [Full Text] [Related]
2. Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine.
Yamashita H; Yoda H; Kuroki N; Kuwabara M; Odagaki Y; Kazawa T; Toyoshima R; Maruki T
Psychopharmacology (Berl); 2011 Jan; 213(1):1-9. PubMed ID: 20820759
[TBL] [Abstract][Full Text] [Related]
3. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
Yamagishi S; Takenaka K; Inoue H
Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
[TBL] [Abstract][Full Text] [Related]
4. The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone.
Yamaguchi K; Tsutsumi E
Intern Med; 2010; 49(10):919-23. PubMed ID: 20467177
[TBL] [Abstract][Full Text] [Related]
5. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
Mori Y; Tanaka T; Matsuura K; Yokoyama J; Utsunomiya K
Adv Ther; 2011 Aug; 28(8):698-706. PubMed ID: 21744143
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan and obesity.
Fernández-Fernández FJ
Intern Med; 2010; 49(19):2191; author reply 2193. PubMed ID: 20930455
[No Abstract] [Full Text] [Related]
7. Telmisartan lowers home blood pressure and improves insulin resistance without correlation between their changes.
Kobayashi K; Ohno Y; Takenaka T; Ikeda N; Okada H; Kanno Y; Suzuki H
Clin Exp Hypertens; 2011; 33(2):100-5. PubMed ID: 21269058
[TBL] [Abstract][Full Text] [Related]
8. Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment.
Fuke Y; Fujita T; Satomura A; Wada Y; Matsumoto K
Diabetes Technol Ther; 2010 May; 12(5):393-8. PubMed ID: 20388049
[TBL] [Abstract][Full Text] [Related]
9. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
Bahadir O; Uzunlulu M; Oguz A; Bahadir MA
Hypertens Res; 2007 Jan; 30(1):49-53. PubMed ID: 17460371
[TBL] [Abstract][Full Text] [Related]
10. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome.
Shimabukuro M; Tanaka H; Shimabukuro T
J Hypertens; 2007 Apr; 25(4):841-8. PubMed ID: 17351377
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
12. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin receptor blocker telmisartan improves insulin sensitivity in peritoneal dialysis patients.
Cioni A; Sordini C; Cavallini I; Bigazzi R; Campese VM
Perit Dial Int; 2010; 30(1):66-71. PubMed ID: 20056982
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial.
Chetty VT; Damjanovic S; Gerstein H; Singh N; Yusuf S; Anand SS; Sharma AM
Blood Press; 2014 Feb; 23(1):54-60. PubMed ID: 23731019
[TBL] [Abstract][Full Text] [Related]
15. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J
Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876
[TBL] [Abstract][Full Text] [Related]
16. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients.
Usui I; Fujisaka S; Yamazaki K; Takano A; Murakami S; Yamazaki Y; Urakaze M; Hachiya H; Takata M; Senda S; Iwata M; Satoh A; Sasaoka T; Ak ND; Temaru R; Kobayashi M
Diabetes Res Clin Pract; 2007 Aug; 77(2):210-4. PubMed ID: 17240472
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients.
Takagi H; Umemoto T;
J Am Soc Hypertens; 2014 Aug; 8(8):578-92. PubMed ID: 25151319
[TBL] [Abstract][Full Text] [Related]
18. Proteinuria in an African HIV-infected patient: effects of telmisartan.
Ucciferri C; Falasca K; Mancino P; Pizzigallo E; Vecchiet J
Infez Med; 2011 Jun; 19(2):125-7. PubMed ID: 21753253
[TBL] [Abstract][Full Text] [Related]
19. Telmisartan increases adiponectin levels: a meta-analysis and meta-regression of randomized head-to-head trials.
Takagi H; Umemoto T
Int J Cardiol; 2012 Mar; 155(3):448-51. PubMed ID: 22192290
[No Abstract] [Full Text] [Related]
20. Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation.
Kurihara T; Ozawa Y; Shinoda K; Nagai N; Inoue M; Oike Y; Tsubota K; Ishida S; Okano H
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5545-52. PubMed ID: 17122147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
